Skip to main content
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

From
To
  • Default content image

    LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits


  • Default content image

    The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models

    Heterozygous mutations in the GBA1 gene--which encodes for lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson’s disease (PD). In addition, decreased GCase…

  • Default content image

    The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology

    As the greatest known genetic contributor to Parkinson's disease (PD), the leucine-rich repeat kinase 2 (LRRK2) gene and protein are targets of interest for Parkinson’s disease research and…

  • Default content image

    Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models

    Mutations and multiplications in the SNCA gene encoding the alpha-synuclein protein are linked to an autosomal dominant form of Parkinson’s disease (PD). One such mutation is the alanine-to-threonine…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…

  • Default content image

    LRRK2 Detection in PBMC Consortium

    The “LRRK2 Detection in PBMC Consortium” is a pre-competitive collaboration between MJFF and select industry partners with the goal of optimizing the measurement of pLRRK2 in human PBMCs. MJFF…

  • Default content image

    Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants

    The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study conducted at over thirty international sites that collects data and biospecimens from idiopathic Parkinson…

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

From
To
  • Default content image

    Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease

    A detailed discussion of our current understanding of alpha-synuclein biology and the ongoing research and development surrounding its role in Parkinson's disease.

  • Default content image

    Diagnosis and Management of Neurodegenerative Atypical Parkinsonism

    A detailed consideration of the neurodegenerative diseases that can cause parkinsonism including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP)…

  • Default content image

    Deep Brain Stimulation and Magnetic Resonance-guided Focused Ultrasound

    A review of innovations in surgical Parkinson's disease treatments, inlcuding deep brain stimulation and magnetic resonance-guided focused ultrasound.

  • Default content image

    Dystonia and Parkinson's Disease

    An exploration of the various manifestations of dystonia in the context of Parkinson's disease.

  • Default content image

    Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys

    A discussion on the latest in new formulations and supplemental therapies of levodopa.

  • Default content image

    Dementia with Lewy Bodies: In the News and in the Clinic

    A practical review of the diagnosis and management of dementia with Lewy bodies.

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

From
To
  • Default content image

    A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease

    Characterisation and diagnosis of idiopathic Parkinson's disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non…

  • Default content image

    Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption

    Parkinson's disease and related synucleinopathies are characterized by the abnormal accumulation of alpha-synuclein aggregates, loss of dopaminergic neurons, and gliosis of the substantia nigra…

  • Default content image

    Fine-mapping of Parkinson's disease susceptibility loci identifies putative causal variants

    Recent genome-wide association studies have identified 78 loci associated with Parkinson's Disease susceptibility but the underlying mechanisms remain largely unclear. To identify variants likely…

  • Default content image

    Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity

    Mutations in GBA1, which encode for the protein glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease and dementia with Lewy bodies. In addition, growing…

  • Default content image

    Predicting Parkinson's Disease and Its Pathology via Simple Clinical Variables

    Background: Parkinson's disease (PD) is a chronic, disabling neurodegenerative disorder. Objective: To predict a future diagnosis of PD using questionnaires and simple non-invasive clinical tests. …

  • Default content image

    Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders

    Mutations in glucocerebrosidase (GBA) are the most prevalent genetic risk factor for Lewy body disorders (LBD)-collectively Parkinson's disease, Parkinson's disease dementia and dementia with Lewy…

  • Default content image

    The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy

    Accumulation of α-synuclein is a main underlying pathological feature of Parkinson's disease and α-synucleinopathies, for which lowering expression of the α-synuclein gene (SNCA) is a potential…

Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.